Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04454918 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04454918 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT04454918, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose administration of 100 microgram (μg) (approximately 1 microcurie \[μCi\]) of \[14C\]-TAK-906 in Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a single oral (solution) administration of 50 mg (approximately 100 μCi) of \[14C\]-TAK-906 in Period 2 (absorption, distribution, metabolism, and elimination \[ADME\]).
Interventions
- DRUG TAK-906 Oral Capsule
- DRUG [14C]-TAK-906 Intravenous Infusion
- DRUG [14C]-TAK-906 Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04454918
The ClinicalTrials.gov registry entry for NCT04454918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAK-906 Oral Capsule is the first listed.
NCT04454918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04454918 about?
NCT04454918 is a clinical study titled "Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants". The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose administration of 100 microgram (μg) (approximately 1 microcurie \[μCi\]) of \[14C\]-TAK-906 in Period 1 (ABA), and to ...
What is the current status of trial NCT04454918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-07-30. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT04454918?
The interventions under investigation include: TAK-906 Oral Capsule (DRUG), [14C]-TAK-906 Intravenous Infusion (DRUG), [14C]-TAK-906 Oral Solution (DRUG).
Who is sponsoring clinical trial NCT04454918?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.